Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic
steatohepatitis (NASH), represent a growing worldwide epidemic and a high unmet medical …

Chronic liver diseases such as nonalcoholic fatty liver disease (NAFLD) or viral hepatitis are
characterized by persistent inflammation and subsequent liver fibrosis. Liver fibrosis critically …

Background Pegozafermin is a long-acting glycopegylated (pegylated with the use of site-
specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development …

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease and is
emerging as the leading cause of cirrhosis, liver transplantation and hepatocellular …

Fibrosis is characterized by the excessive extracellular matrix deposition due to
dysregulated wound and connective tissue repair response. Multiple organs can develop …

Non-alcoholic fatty liver disease (NAFLD) includes a range of hepatic manifestations,
starting with liver steatosis and potentially evolving towards non-alcoholic steatohepatitis …

Background Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need.
Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that …

Non-alcoholic fatty liver disease (NAFLD) has emerged pandemically across the globe and
particularly affects patients with obesity and type 2 diabetes. NAFLD is a complex systemic …

Non-alcoholic fatty liver disease (NAFLD) is regarded as a pandemic that affects about a
quarter of the global population. Recently, host-gut microbiota metabolic interactions have …

The multimodal activities of farnesoid X receptor (FXR) agonists make this class an attractive
option to treat nonalcoholic steatohepatitis. The safety and efficacy of tropifexor, an FXR …